Richard Staines discusses what has become one of the worst deals in pharma’s history – AbbVie’s purchase of Stemcentrx and its lung cancer drug Rova-T. Rova-T was supposed to be the cancer ...

AbbVie holds a strong portfolio of marketed ... and the $6 billion acquisition of Stemcentrx looks like poor judgment on a key cancer drug that looks less effective in late-stage clinical studies.

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...

AbbVie (ABBV) and Xilio Therapeutics (XLO) announced a collaboration and option-to-license agreement to develop novel tumor-activated, ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...

Under CollPlant’s (CLGN) existing development and commercialization agreement, CollPlant has granted AbbVie (ABBV) a worldwide exclusive license to use CollPlant’s rhCollagen technology in ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., winning an ...

Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...

AbbVie previously acquired Stemcentrx in a $5.8bn deal in 2016 to gain access to an ADC targeting small cell lung cancer, but the drug ultimately failed to make a mark in clinical studies.

AbbVie CEO Robert Michael will soon add the role of board chairman to his résumé. Michael, who became CEO of the North Chicago-based pharmaceutical giant last summer, will assume duties as ...